US2004043052A1PendingUtilityA1

Compositions and methods for coating medical implants

54
Assignee: ANGIOTECH PHARM INCPriority: May 24, 2002Filed: May 27, 2003Published: Mar 4, 2004
Est. expiryMay 24, 2022(expired)· nominal 20-yr term from priority
A61L 29/16A61L 2300/416A61L 2300/404A61L 29/085A61P 43/00A61P 31/00A61L 27/34A61L 27/54
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . A medical implant which releases an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.  
     
     
         2 . The medical implant according to  claim 1  wherein said implant is covered or coated in whole or in part with a composition comprising an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.  
     
     
         3 . The medical implant according to  claim 1  or  2  wherein said anthracycline is doxorubicin or mitoxantrone.  
     
     
         4 . The medical implant according to  claim 1  or  2  wherein said fluoropyrimidine is 5-fluorouracil.  
     
     
         5 . The medical implant according to  claim 1  or  2  wherein said folic acid antagonist is methotrexate.  
     
     
         6 . The medical implant according to  claim 1  or  2  wherein said podophylotoxin is etoposide.  
     
     
         7 . The medical implant according to  claim 2  wherein said composition further comprises a polymer.  
     
     
         8 . The medical implant according to  claim 7  wherein said polymer is a biodegrable or a non-biodegradable polymer.  
     
     
         9 . The medical implant according to  claim 7  wherein said polymer is a polyurethane.  
     
     
         10 . The medical implant according to  claim 7  wherein said polymer is a poly(lactide-co-glycolide).  
     
     
         11 . The medical implant according to any one of  claims 7  to  10  wherein said fluoropyrimidine is 5-fluorouracil.  
     
     
         12 . The medical implant according to  claim 1  or  2  wherein said medical implant is a vascular catheter, prosthetic heart valve, cardiac pacemaker, implantable cardioverter defibrillator, vascular graft, ear, nose, or throat implant, urological implant, endotracheal or tracheostomy tube, dialysis catheter, CNS shunt, orthopedic implant, or ocular implant.  
     
     
         13 . A composition, comprising a polymer and an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than 10 −4  M.  
     
     
         14 . The composition according to  claim 13  wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex, wherein said anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex is present in said composition at a concentration of less than any one of 10 −5  M, 10 −6  M, or 10 −7  M.  
     
     
         15 . The composition according to  claim 13  wherein said polymer is a biodegrable or a non-biodegradable polymer.  
     
     
         16 . The medical implant according to  claim 13  wherein said polymer is a polyurethane.  
     
     
         17 . The medical implant according to  claim 13  wherein said polymer is a poly(lactide-co-glycolide).  
     
     
         18 . The composition according to any one of  claims 13  to  17  wherein said fluoropyrimidine is 5-fluorouracil.  
     
     
         19 . A method for reducing or inhibiting infection associated with a medical implant, comprising the step of introducing into a patient a medical implant which has been covered or coated with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.  
     
     
         20 . The method according to  claim 19  wherein said fluoropyrimidine is 5-fluorouracil.  
     
     
         21 . A method for making medical implants, comprising covering or coating a medical implant with an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, or platinum complex.  
     
     
         22 . The method according to  claim 21  wherein said fluoropyrimidine is 5-fluorouracil.  
     
     
         23 . The method according to  claim 21  wherein said medical implant covered or coated by dipping or by impregnation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.